더바이오 10월 14일 주요뉴스 [https://www.thebionews.net/edit/webzine.html?idxno=662](https://www.thebionews.net/edit/webzine.html?idxno=662) ●[컨콜] J&J, ‘리브리반트·렉라자’ 3Q 매출 첫 3억달러 돌파…전년比 62%↑ [https://www.thebionews.net/news/articleView.html?idxno=28998](https://www.thebionews.net/news/articleView.html?idxno=28998) ●항암제 초기 임상, 어디까지 허용되나…“식약처, 임상 참여 기준 후속 정비” [https://www.thebionews.net/news/articleView.html?idxno=28989](https://www.thebionews.net/news/articleView.html?idxno=28989) ●조현선 핀테라 대표 “새 단백질분해제 ‘핀마스’ 플랫폼, 글로벌 L/O 도전” [https://www.thebionews.net/news/articleView.html?idxno=28993](https://www.thebionews.net/news/articleView.html?idxno=28993) ●백규석 큐리에이터 대표 “동물 약효 데이터 없이 항암제 병용 임상 근거 확보” [https://www.thebionews.net/news/articleView.html?idxno=28992](https://www.thebionews.net/news/articleView.html?idxno=28992) ●국내 연구팀, 내성 폐암에 ‘렉라자·화학요법’ 병용 2상 성공…mPFS 9.5개월 [https://www.thebionews.net/news/articleView.html?idxno=29030](https://www.thebionews.net/news/articleView.html?idxno=29030) ●“체중 감량 30% 시대”…일라이릴리가 제시한 차세대 비만 치료 개발 전략은 [https://www.thebionews.net/news/articleView.html?idxno=29024](https://www.thebionews.net/news/articleView.html?idxno=29024) ●“글로벌 임상 첫 환자 등록 때 韓 기관 가동률 20%…개시 절차 개선 필요” [https://www.thebionews.net/news/articleView.html?idxno=29039](https://www.thebionews.net/news/articleView.html?idxno=29039) ●EMA 종양학 자문위원 “항암신약 성공 기준, 통계적 유의성 넘어 환자 가치” [https://www.thebionews.net/news/articleView.html?idxno=29004](https://www.thebionews.net/news/articleView.html?idxno=29004) ●한미약품, 신약개발 AI 플랫폼 ‘HARP’ 고도화…신약 설계부터 임상까지 확장 [https://www.thebionews.net/news/articleView.html?idxno=29043](https://www.thebionews.net/news/articleView.html?idxno=29043) ●인벤티지랩, 12개월 지속 초장기 동물용 의약품 美 특허 등록 결정 [https://www.thebionews.net/news/articleView.html?idxno=29033](https://www.thebionews.net/news/articleView.html?idxno=29033) ●獨 바이오엔테크 ‘mRNA 암백신’ BNT113, 두경부암 2·3상 PFS 개선 실패 [https://www.thebionews.net/news/articleView.html?idxno=29036](https://www.thebionews.net/news/articleView.html?idxno=29036) ●릴리, 美 프렐류드와 ‘KAT6A 분해제’ 유방암 병용 임상 협력…버제니오 공급 [https://www.thebionews.net/news/articleView.html?idxno=29035](https://www.thebionews.net/news/articleView.html?idxno=29035) ●MSD, ‘ESMO 2026’서 핵심 3상 3건 첫 공개…인티스메란·Sac-TMT 주목 [https://www.thebionews.net/news/articleView.html?idxno=28995](https://www.thebionews.net/news/articleView.html?idxno=28995) ●산업부·식약처, 바이오 AI 전환 맞손…기술개발·수출 협력 [https://www.thebionews.net/news/articleView.html?idxno=29029](https://www.thebionews.net/news/articleView.html?idxno=29029) ●동구바이오, 잇단 투자 성과 주목…큐리언트·디앤디파마텍·노바셀 사업 진전 [https://www.thebionews.net/news/articleView.html?idxno=29041](https://www.thebionews.net/news/articleView.html?idxno=29041) ●지투지바이오, ‘PODD 2026’서 초고농축 항체 SC 플랫폼 글로벌 첫선 [https://www.thebionews.net/news/articleView.html?idxno=29040](https://www.thebionews.net/news/articleView.html?idxno=29040) ●GC녹십자, LG CNS와 전략적 파트너십…AI 기반 ‘스마트팩토리’ 구축 [https://www.thebionews.net/news/articleView.html?idxno=29038](https://www.thebionews.net/news/articleView.html?idxno=29038) ●메디포스트, 29일 임시 주총서 민호성 사내이사 선임…각자대표 전환 추진 [https://www.thebionews.net/news/articleView.html?idxno=29037](https://www.thebionews.net/news/articleView.html?idxno=29037) ●HLB파나진, ‘OTS 2026’서 AOC 플랫폼 주요 기술 포스터 발표 [https://www.thebionews.net/news/articleView.html?idxno=29025](https://www.thebionews.net/news/articleView.html?idxno=29025) ●에스티큐브, ESMO서 ‘넬마스토바트’ 3개 개발축 공개…병용 확장 전략 발표 [https://www.thebionews.net/news/articleView.html?idxno=29018](https://www.thebionews.net/news/articleView.html?idxno=29018) ●“The era of 30% weight loss” dawns as Eli Lilly presents its next-generation obesity treatment development strategy [https://www.thebionews.net/news/articleView.html?idxno=29042](https://www.thebionews.net/news/articleView.html?idxno=29042) ●Celltrion’s ‘Omlyclo’ competitiveness spotlighted in Japan as ‘first mover’ launch arrives [https://www.thebionews.net/news/articleView.html?idxno=29034](https://www.thebionews.net/news/articleView.html?idxno=29034) ●Pin Therapeutics CEO Jo Hyun-sun: “Taking on global L/O with ‘PinMARS,’ a new protein-degrading agent platform” [https://www.thebionews.net/news/articleView.html?idxno=29032](https://www.thebionews.net/news/articleView.html?idxno=29032) ●Shaperon's theoretical paper on 'limitations of steroid effects' accepted by international journal [https://www.thebionews.net/news/articleView.html?idxno=29031](https://www.thebionews.net/news/articleView.html?idxno=29031) ●Orum Therapeutics Doses First Patient in Phase 1 Trial of ORM-1153, a CD123-GSPT1 Degrader-Antibody Conjugate [https://www.thebionews.net/news/articleView.html?idxno=29003](https://www.thebionews.net/news/articleView.html?idxno=29003) *제약바이오 10월 14일 아침 유튜브 라디오 뉴스(매일 아침 업로드) [https://www.youtube.com/watch?v=V6XloqazvFg](https://www.youtube.com/watch?v=V6XloqazvFg)